Disclosed CapitolDisclosedCapitol
Home
Plans
Chad AI
API
Sign InGet Pro

Never Miss a Trade

Get weekly trade alerts free.

Explore

  • Politician Trades
  • Politicians
  • Executive Branch
  • Companies
  • All Stocks A–Z
  • Leaderboard
  • Compare Politicians
  • Committee Portfolios
  • Chad AI

Money & Policy

  • Government Contracts
  • Lobbying
  • Legislation
  • Campaign Finance
  • Institutional (13F)
  • Whale Watch (13D)

Markets

  • Markets Overview
  • Top Companies
  • Insider Trends
  • Economic Indicators
  • Live News

Resources

  • API Access
  • Developers
  • Data Export
  • Glossary
  • Methodology
  • Data Sources
  • How It Works

Company

  • About Us
  • Press
  • FAQ
  • Pricing
  • vs. Capitol Trades
  • Contact
  • Watchlist

Legal

  • Editorial Standards
  • Corrections
  • Disclaimers
  • Privacy
  • Terms
© 2026 Disclosed Capitol. All rights reserved.
TermsPrivacyDisclaimer
HomeTrades
Chad
WatchlistAccount

GDRX

Healthcare
GoodRx Holdings, Inc. · Health Information Services
Trades
4
Politicians
0
Buys
3
Sells
1
Trades
4
Politicians
0
Buys
3
Sells
1
GDRXvs S&P 500 (normalized)
|to
No price data available
GDRX S&P 500 Buy Sell
Range
PoliticianActionDescriptionAmountTradedFiled
Ro KhannaD
SellGARTNER, INC. CMN$1K - $15KAug 26, 2025Sep 9, 2025
Greg SteubeR
BuyGOODRX HOLDINGS INC$15K - $50KJul 10, 2025Jul 16, 2025
Ro KhannaD
BuyGOODRX HOLDINGS INC CMN$1K - $15KApr 13, 2022Apr 21, 2022
Ro KhannaD
BuyGOODRX HOLDINGS INC CMN CLAS$1K - $15KMar 31, 2022Apr 1, 2022

GoodRx Holdings, Inc. (GDRX) Congressional Stock Trades

This page tracks congressional stock trading activity in GoodRx Holdings, Inc. (GDRX) in the Healthcare sector. Disclosed Capitol has indexed 4 disclosed congressional trades involving GDRX. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.

As of September 2025 — Disclosed Capitol has tracked 4 disclosed congressional trades in GoodRx Holdings, Inc. (GDRX) — 3:1 buy-heavy ratio — led by Ro Khanna (D).

Which members of Congress trade GoodRx Holdings, Inc.?

  • Ro Khanna (D) — 3 disclosed trades in GDRX
  • Greg Steube (R) — 1 disclosed trade in GDRX

Recent GDRX congressional trades

DatePoliticianPartyActionAmount
Aug 26, 2025Ro KhannaDSale$1,001 - $15,000
Jul 10, 2025Greg SteubeRPurchase$15,001 - $50,000
Apr 13, 2022Ro KhannaDPurchase$1,001 - $15,000
Mar 31, 2022Ro KhannaDPurchase$1,001 - $15,000

Buy vs. sell ratio & volume

Across the 4 disclosed congressional trades in GoodRx Holdings, Inc. (GDRX), members of Congress have reported 3 buys and 1 sell. The average 30-day alpha vs. the S&P 500 is -26.72%.

Are GoodRx Holdings, Inc. insiders buying or selling GDRX?

As of August 2026, corporate insiders at GoodRx Holdings, Inc. have filed 18 SEC Form 4 transactions in GDRX over the past 12 months — including 14 sells worth $9.7M.

DateInsiderActionValue
2026-08-26Francisco Partners Management, LPSale$750K
2026-08-26Francisco Partners Management, LPSale$739K
2026-08-26Francisco Partners Management, LPSale$1.5M
2026-08-26Francisco Partners Management, LPSale$1.5M
2026-08-25Francisco Partners Management, LPSale$221K
2026-08-25Francisco Partners Management, LPSale$218K
2026-08-24Francisco Partners Management, LPSale$250K
2026-08-24Francisco Partners Management, LPSale$247K
2026-08-21Francisco Partners Management, LPSale$484K
2026-08-21Francisco Partners Management, LPSale$477K

Insider transactions are parsed from SEC Form 4 filings and shown alongside the congressional trades above. Institutional 13F positions are tracked separately on the institutional holdings page.

GoodRx Holdings, Inc. financial snapshot (FY2025)

For fiscal year 2025, GoodRx Holdings, Inc. reported revenue of $796.9M and net income of $30.4M, per SEC filings.

Revenue
$796.9M
Operating income
$87.5M
Net income
$30.4M
Diluted EPS
$0.09
Net margin
3.8%
Free cash flow
$164.4M

Most recent reported quarter: Q2 FY2026 — revenue $394.4M, net income $9.7M.

Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.